Immuneering Corporation (NASDAQ:IMRX) is among the best fast money stocks to buy now. Analysts at Mizuho have reaffirmed their ‘Outperform’ rating on Immuneering Corporation (NASDAQ:IMRX), while maintaining a price target of $10, implying a surge of about 43%. This optimism stems from the company’s positive clinical trial outcome for its lead drug candidate.
On Wednesday, Immuneering Corporation reported modified 9-month survival data from its Phase 2a trial of atebimetinib (atebi), together with updated gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. The data, collected from 34 patients, reflected overall survival and progression-free survival results that not only surpassed the traditional standard-of-care treatments, but also the research firm’s own expectations.
What keeps the investor’s interest is the company’s atebimetinib, which has the potential to become a top-tier treatment for first-line pancreatic cancer patients. With the results demonstrating enhanced durability in contrast to the previous 6-month data update from June, we have a good reason to believe in the prospects of the drug, and ultimately Immuneering Corporation.
Immuneering Corporation is a Massachusetts-based clinical-stage oncology company specializing in treatments targeting broad populations of cancer patients. Founded in 2008, the company is committed to developing innovative medicines.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
